Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Otitis externa - Management
Who should avoid using a topical ear preparation?

  • People with (or history of) a local sensitivity reaction should avoid preparations with the same class of drug associated with the reaction. For example, if neomycin is thought to have caused a sensitivity reaction all preparations containing aminoglycosides should be avoided.
  • People who have a perforated tympanic membrane should avoid topical aminoglycosides.
Clarification / Additional information
  • Sensitivity reactions:
  • Ototoxicity with aminoglycoside antibiotics:
    • The Committee on Safety of Medicines (CSM) advises that topical ear canal treatment with aminoglycosides is contraindicated in people with a tympanic perforation [CSM, 1997].
Table 1. Compounds from topical ear preparations reported to cause sensitization.
Group
Chemicals
Antibiotics
Aminoglycosides
Neomycin
Gentamicin sulphate 1%
Framycetin
Polymyxin B sulphate
Chloramphenicol
Bacitracin
Corticosteroids
Hydrocortisone
Excipients
Benzethonium chloride (preservative)
Benzalkonium chloride 0.1% (preservative)
Caine mix
Methyl-methacrylate
Methyl-p-oxybenzoate (preservative)
Methylrosaniline (Gentian violet)
Nickel sulphate 5%
Propylene glycol (preservative)
Quinolone mix 6%
Thimerosal merthiolate (preservative)
Data from: [Sood et al, 2002]

© NHS Institute for Innovation and Improvement